| Citation: |
GAN Wanling, HAN Chenyan, HAN Fangfang, ZHANG Ming, LIU Xiaoxin. Application of distance education guidance in patients with immunotherapy for lung cancer[J]. Journal of Clinical Medicine in Practice, 2022, 26(24): 41-45. DOI: 10.7619/jcmp.20221616
|
To investigate the effect of distance education guidance on immune-related adverse events (irAEs) and quality of life in patients with non-small cell lung cancer (NSCLC).
A total of 56 NSCLC patients receiving immunotherapy were selected as control group, and another 56 NSCLC patients receiving immunotherapy were selected as trail group. The control group was given regular education guidance, while the trial group was given distance education guidance, including the establishment of a distance education team, the construction of a network education platform, standardized health education, multi-dimensional health education, and the online distance guidance of irAEs. The incidence and severity of irAEs after intervention, quality of life before and after intervention, satisfaction rate and re-admission rate were compared between the two groups.
At three months after intervention, the incidence rates of nausea, abdominal pain, arthralgia and diarrhea in the trial group were lower than those in the control group (P>0.05). Compared with the control group, the severity of skin dryness, itching, rash, fatigue and cough in the trial group was lower (P>0.05). At six months after intervention, the total score of quality of life in the trail group was (113.41±6.02), which was significantly higher than (98.23±2.01) in the control group (P < 0.05). At six months after intervention, the total satisfaction rate of the trail group was 94.64% (53/56), which was significantly higher than 82.14% (46/56) of the control group (P=0.039); the re-admission rate of the trail group was 10.71% (6/56), which was significantly lower than 25.00% (14/56) of the control group (P=0.048).
Distance education guidance can promote the online communication between doctors and patients, reduce the re-admission rate of patients, improve the satisfaction rate of NSCLC patients, and improve the quality of life of patients.
| [1] |
SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33. doi: 10.3322/caac.21654
|
| [2] |
VÇVET A, GVRSOY S, YAZGAN S. Changes in the surgical treatment strategies for nonsmall cell lung cancer in the past 20 years: a single-center experience[J]. Turk Thorac J, 2020, 21(1): 8-13. doi: 10.5152/TurkThoracJ.2019.180124
|
| [3] |
韩燕红, 吴红艳, 成方, 等. 肺癌患者治疗相关性症状与生活质量及功能状况的关系研究[J]. 护理学杂志, 2021, 36(20): 36-39. doi: 10.3870/j.issn.1001-4152.2021.20.036
|
| [4] |
李浩洋, 王敬慧. 晚期非小细胞肺癌免疫治疗进展[J]. 中国肺癌杂志, 2021, 24(2): 131-140. https://www.cnki.com.cn/Article/CJFDTOTAL-FAIZ202102010.htm
|
| [5] |
ANTONIA S J, VILLEGAS A, DANIEL D, et al. Overall survival with durvalumab after chemoradiotherapy in stage Ⅲ NSCLC[J]. N Engl J Med, 2018, 379(24): 2342-2350. doi: 10.1056/NEJMoa1809697
|
| [6] |
ZHANG L P, WANG J, ZHANG B C, et al. Attitudes and practices of immune checkpoint inhibitors in Chinese patients with cancer: a national cross-sectional survey[J]. Front Pharmacol, 2021, 12: 583126. doi: 10.3389/fphar.2021.583126
|
| [7] |
WOOD L S, MOLDAWER N P, LEWIS C. Immune checkpoint inhibitor therapy: key principles when educating patients[J]. Clin J Oncol Nurs, 2019, 23(3): 271-280.
|
| [8] |
JENSEN B T, KRISTENSEN S A, CHRISTENSEN S V, et al. Efficacy of tele-nursing consultations in rehabilitation after radical prostatectomy: a randomised controlled trial study[J]. Int J Urol Nurs, 2011, 5(3): 123-130. doi: 10.1111/j.1749-771X.2011.01130.x
|
| [9] |
HOFFNER B, RUBIN K M. Meeting the challenge of immune-related adverse events with optimized telephone triage and dedicated oncology acute care[J]. J Adv Pract Oncol, 2019, 10(Suppl 1): 9-20.
|
| [10] |
National Health Commission of the People's Republic of China. 原发性肺癌诊疗规范(2018年版)[J]. 肿瘤综合治疗电子杂志, 2019, 5(3): 100-120. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLZD201903017.htm
|
| [11] |
GOLDSTRAW P, CHANSKY K, CROWLEY J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer[J]. J Thorac Oncol, 2016, 11(1): 39-51. doi: 10.1016/j.jtho.2015.09.009
|
| [12] |
倪军, 黄淼, 张力, 等. 非小细胞肺癌围手术期免疫治疗相关不良反应管理的临床诊疗建议[J]. 中国肺癌杂志, 2021, 24(3): 141-160. https://www.cnki.com.cn/Article/CJFDTOTAL-FAIZ202103001.htm
|
| [13] |
HAANEN J B A G, CARBONNEL F, ROBERT C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29(Suppl 4): iv264-iv266.
|
| [14] |
NEERACKAL R J, ABDUL LATHEEF E N, SUKUMARAKURUP S, et al. Relaxation therapy in the management of psoriasis[J]. Dermatol Ther, 2020, 33(6): e14030.
|
| [15] |
甘婉玲, 韩辰燕, 刘晓芯, 等. 肺癌患者免疫治疗所致皮肤毒性反应症状研究[J]. 实用临床医药杂志, 2021, 25(22): 21-25. doi: 10.7619/jcmp.20212148
|
| [16] |
LICHTERFELD-KOTTNER A, EL GENEDY M, LAHMANN N, et al. Maintaining skin integrity in the aged: a systematic review[J]. Int J Nurs Stud, 2020, 103: 103509. doi: 10.1016/j.ijnurstu.2019.103509
|
| [17] |
DUECK A C, MENDOZA T R, MITCHELL S A, et al. Validity and reliability of the US national cancer institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)[J]. JAMA Oncol, 2015, 1(8): 1051-1059. doi: 10.1001/jamaoncol.2015.2639
|
| [18] |
STEFFEN MCLOUTH L E, LYCAN T W Jr, LEVINE B J, et al. Patient-reported outcomes from patients receiving immunotherapy or chemoimmunotherapy for metastatic non-small-cell lung cancer in clinical practice[J]. Clin Lung Cancer, 2020, 21(3): 255-263, e4. doi: 10.1016/j.cllc.2019.11.015
|
| [19] |
CELLA D F, TULSKY D S, GRAY G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure[J]. J Clin Oncol, 1993, 11(3): 570-579. doi: 10.1200/JCO.1993.11.3.570
|
| [20] |
江昌, 易玲, 高翔, 等. 非小细胞肺癌免疫治疗生物标志物研究进展[J]. 中国肺癌杂志, 2022, 25(1): 46-53. https://www.cnki.com.cn/Article/CJFDTOTAL-FAIZ202201006.htm
|
| [21] |
华雨薇, 赵林. 免疫治疗相关不良反应研究进展[J]. 中华胃肠外科杂志, 2022, 25(3): 271-276. https://www.cnki.com.cn/Article/CJFDTOTAL-XYWS202202017.htm
|
| [22] |
周静, 王永才, 汪鑫. 基于微信平台对癌痛患者出院后延续护理效果的分析[J]. 中国卫生信息管理杂志, 2018, 15(4): 457-460. https://www.cnki.com.cn/Article/CJFDTOTAL-WSGL201804024.htm
|
| [23] |
HINTISTAN S, NURAL N, CILINGIR D, et al. Therapeutic effects of nurse telephone follow-up for lung cancer patients in Turkey[J]. Cancer Nurs, 2017, 40(6): 508-516.
|
| [24] |
BOULEFTOUR W, MURON T, GUILLOT A, et al. Effectiveness of a nurse-led telephone follow-up in the therapeutic management of patients receiving oral antineoplastic agents: a randomized, multicenter controlled trial (ETICCO study)[J]. Support Care Cancer, 2021, 29(8): 4257-4267.
|
| [25] |
LARSON J L, ROSEN A B, WILSON F A. The effect of telehealth interventions on quality of life of cancer survivors: a systematic review and meta-analysis[J]. Health Informatics J, 2020, 26(2): 1060-1078.
|
| 1. |
田文，高晓明，姚皓月，武丹. 肿瘤免疫治疗患者信息需求的研究进展. 中华现代护理杂志. 2024(25): 3496-3500 .
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: